Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus

21Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Allogeneic mesenchymal stem cell (MSC) transplantation has recently become a promising therapy for patients with systemic lupus erythematosus (SLE). MSCs are a kind of multipotent stem cell than can efficiently modulate both innate and adaptive immune responses, yet those from SLE patients themselves fail to maintain the balance of immune cells, which is partly due to the abnormal genetic background. Clarifying genetic factors associated with MSC dysfunction may be helpful to delineate SLE pathogenesis and provide new therapeutic targets. In this review, the scientific evidence on the genetic contribution to MSC dysfunction in SLE is summarized.

Cite

CITATION STYLE

APA

Zhu, Y., & Feng, X. (2018, May 24). Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. Stem Cell Research and Therapy. BioMed Central Ltd. https://doi.org/10.1186/s13287-018-0898-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free